BYOT.L

Byotrol Plc
Byotrol PLC - Board Changes
27th September 2023, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 7478N
Byotrol PLC
27 September 2023
 

 

Byotrol plc

("Byotrol" or the "Company")

Board Changes

Byotrol Plc (AIM: BYOT), the specialist infection prevention and control company, announces that Vivan Pinto, CEO of the Company, has stepped down as CEO and left the Company to pursue other opportunities.

 

David Traynor formerly Byotrol CEO 2013 - 2022 has kindly agreed to act as interim CEO until a suitable replacement for Vivan is appointed.

 

 

Trevor Francis, Chairman of Byotrol, commented:

 

"From the time that Vivan took over from David Traynor as CEO, he was committed to drive forward the Company strategy and build the organisation for the exciting opportunities that we all believe are achievable. The Board thanks Vivan for all his efforts over the last 20 months and would like to wish Vivan well for the future".

 

 

Enquiries:

 

Byotrol Plc


Trevor Francis - Chairman

David Traynor - CEO

+44 (0)1925 742 000

Chris Sedwell - Chief Financial Officer




Cavendish Capital Markets Limited (Nominated Adviser and Broker)

+44 (0)20 7220 0500

Geoff Nash / George Dollemore - Corporate Finance


Nigel Birks / Harriet Ward - ECM




Flagstaff Strategic and Investor Communications

+44 (0)20 7129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon                                              

 

byotrol@flagstaffcomms.com

 

 

This announcement is released by Byotrol Plc and, prior to publication, the information contained herein was deemed to constitute inside information under the Market Abuse Regulations (EU) No. 596/2014. Such information is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.

 

Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.

 

For more information, go to byotrol.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFLFITAFIRFIV ]]>
TwitterFacebookLinkedIn